Trevi Therapeutics Newsroom

D. Boral Capital Maintains Buy on Trevi Therapeutics, Maintains $21 Price Target

BenzingaDec 16 15:34 ET

Trevi Therapeutics Analyst Ratings

BenzingaDec 16 15:33 ET

Analysts Offer Insights on Healthcare Companies: Affimed (AFMD), Editas Medicine (EDIT) and Trevi Therapeutics (TRVI)

TipRanksDec 16 01:13 ET

A Quick Look at Today's Ratings for Trevi Therapeutics(TRVI.US), With a Forecast Between $6 to $9

Moomoo NewsDec 13 08:00 ET

Trevi Therapeutics Price Target Raised to $7.50/Share From $6.00 by HC Wainwright & Co.

Dow JonesDec 12 13:02 ET

Trevi Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow JonesDec 12 13:02 ET

Trevi Therapeutics Analyst Ratings

BenzingaDec 12 12:22 ET

Optimistic Buy Rating for Trevi Therapeutics Amid Promising Phase 2b Trial Results

TipRanksDec 12 08:59 ET

Oppenheimer Remains a Buy on Trevi Therapeutics (TRVI)

TipRanksDec 5 11:51 ET

B.Riley Financial Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $6

Moomoo NewsDec 5 10:33 ET

D. Boral Capital Maintains Buy on Trevi Therapeutics, Maintains $21 Price Target

BenzingaDec 4 07:28 ET

Trevi Therapeutics Price Target Maintained With a $8.00/Share by Needham

Dow JonesDec 4 06:33 ET

Trevi Therapeutics Analyst Ratings

BenzingaDec 4 06:23 ET

JonesTrading Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $8

Moomoo NewsNov 19 03:36 ET

B.Riley Financial Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $6

Moomoo NewsNov 8 13:31 ET

Needham Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $8

Moomoo NewsNov 7 16:31 ET

Stifel Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Announces Target Price $8

Moomoo NewsNov 7 10:31 ET

Trevi Therapeutics Price Target Maintained With a $21.00/Share by EF Hutton

Dow JonesNov 7 09:00 ET

Trevi Therapeutics Is Maintained at Buy by EF Hutton

Dow JonesNov 7 09:00 ET

Trevi Therapeutics Analyst Ratings

BenzingaNov 7 08:50 ET